Stem cells in ductal breast cancer: immunohistochemical expression of CD44, CD24, CD133, and ALDH-1 markers in 104 cases

Objective: The aim of this study was to evaluate the immunohistochemical expression of stem cell markers CD44, CD24, CD133, and ALDH-1 in breast carcinomas and investigate any correlation with stage, degree of tumor differentiation, cell proliferation index, and hormone receptors status. Materials and Methods: One hundred and four cases of invasive ductal breast carcinomas were studied and classified according to grade and stage, hormonal status, and C-erbB2 expression. A semi-automatic Ventana method was used to examine by semi-quantitative method the immunohistochemical expression of anti-CD133, CD24, CD44, and ALDH1 antibodies. Results: CD44, CD24, and ALDH1 markers demonstrated a statistically significant correlation with higher disease stage and triple negative cancers (94%-55.5%). CD133 correlated with triple negative cancers (55.5%). No correlation with other clinical data or tumor differentiation was observed. Conclusion: Triple negative breast cancers express specific stem cell markers responsible for cell/stroma interaction and this is a useful tool in predicting tumor progression and developing specific targeted therapies.

Breast cancer; Stem cells; CD44; CD24; CD133; ALDH1.

[1] “WHO Classification of Tumors of the Breast”. (eds.) Lakhani S.R., Ellis I.O., Schnitt S.J., Tan P.H., van de Vijver M.J. Lyon: IARC Press, 2012, 4th ed, vol. 4.

[2] Fillmore C.M., Kuperwasser C.: “Human breast cancer cell lines con tain stem-like cells that self-renew, give rise to phenotypically di verse progeny and survive chemotherapy”. Breast Cancer Res., 2008, 10, R25.

[3] Ponti D., Costa A., Zaffaroni N., Pratesi G., Petrangolini G., Coradini D., et al.: “Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell proper ties”. Cancer Res., 2005, 65, 5506.

[4] Wright M.H., Calcagno A.M., Salcido C.D., Carlson M.D., Ambudkar S.V., Varticovski L.: “Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics”. Breast Cancer Res., 2008, 10, R10.

[5] Corti S., Locatelli F., Papadimitriou D., Donadoni C., Salani S., Del Bo R., et al.: “Identification of a primitive brain- derived neural stem cell population based on aldehyde dehydroge nase activity”. Stem Cells, 2006, 24, 975.

[6] Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L.: “Human breast cancer: correlation of relapse and survival with am plification of the HER-2/neu oncogene”. Science, 1987, 235, 177.

[7] Wicha M.S., Liu S., Dontu G.: “Cancer stem cells: an old idea-a para digm shift”. Cancer Res., 2006, 66, 1883.

[8] Bourguignon L.Y., Peyrollier K., Xia W., Gilad E.: “HyaluronanCD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells”. J. Biol. Chem., 2008, 283, 17635.

[9] Lacerda L., Pusztai L., Woodward W.A.: “The role of tumor initiating cells in drug resistance of breast cancer: implications for future therapeutic approaches”. Drug Resist. Updat., 2010, 13, 99.

[10] Croker A.K., Goodale D., Chu J., Postenka C., Hedley B.D., Hess D.A., et al.: “High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability”. J. Cell. Mol. Med., 2009, 13, 2236.

[11] Bourguignon L.Y., Gilad E., Peyrollier K.: “Heregulin-mediated ErbB2- ERK signaling activates hyaluronan synthases leading to CD44- dependent ovarian tumor cell growth and migration”. J. Bio. Chem., 2007, 282, 19426.

[12] Sheridan C., Kishimoto H., Fuchs R.K., Mehrotra S., Bhat-Nakshatri P., Turner C.H., et al.: “CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis”. Breast Cancer Res., 2006, 8, R59.

[13] Abraham B.K., Fritz P., McClellan M., Hauptvogel P., Athelogou M., Brauch H.: “Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis”. Clin. Cancer Res., 2005, 11, 1154.

[14] Charafe-Jauffret E., Ginestier C., lovino F., Tarpin C., Diebel M., EsterniB., et al.: “Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer”. Clin. Cancer Res., 2010, 16, 45.

[15] Neumeister V., Agarwal S., Bordeaux J., Camp R.L., Rimm D.L.: “In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis”. Am. J. Pathol., 2010, 176, 2131.

[16] Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., et al.: “Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer”. Cell Stem Cell, 2007, 1, 313.

[17] Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E.: “Targeting of CD44 eradicates human acute myeloid leukemic stem cells”. Nat. Med., 2006, 12, 1167.

[18] Park S.O.Y., Lee H.E., Li H., Shipitsin M., Gelman R., Polyak K.: “Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer”. Clin. Cancer Res., 2010, 16, 876.

[19] Platt V.M, Szoka F.C. Jr: “Anticancer therapeutics: targeting macromol ecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor”. Mol. Pharm., 2008, 5, 474.

[20] Kristiansen G.: “CD24 expression is a new prognostic marker in breast cancer”. Clin. Cancer Res., 2003, 9, 4906.

[21] Kristiansen G.: “CD24 is an independent prognostic marker of survival in non small cell cancer patients”. Br. J. Cancer, 2003, 8, 231.

[22] Kristiansen G.: “CD24 is expressed in ovarian cancer”. Am. J. Pathol., 2002, 161, 1215.

[23] Baumann P., Cremers N., Kroese F., Orend G., Chiquet-Ehrisman R., Uede T., et al.: “CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis”. Cancer Res., 2005, 65, 10783.

[24] LaBarge M.A., et Bissell M.J.: “Is CD133 a marker of metastatic colon cancer stem cells ?” J. Clin. Invest., 2008, 118, 2021.

[25] Wright M.H.: “BRCA1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics”. Breast Can-cer Res., 2008, 10, R10.

[26] Kim M.P., Fleming J.B., Wang H., Abbruzzese J.L., Choi W., Kopetz S., et al.: “ALDH activity selectively defines an enhanced tumor initiating cell population relative to CD 133 expression in human pancreatic adenocarcinoma”. PLoS One, 2011, 6, e20636.

[27] Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F.: “Prospective identification of tumorigenic breast cancer cells” Proc. Natl. Acad. Sci. U S A, 2003, 100, 3983. [28] Ginestier C., Liu S., Diebel M.E., Korkaya H., Luo M., Brown M.: “CXCR1 blockade selectively targets human breast can cer stem cells in vitro and in xenografts”. J. Clin. Invest., 2010, 120, 485.